Patent intelligence · US
US 10344271
Modified zinc finger binding proteins
Modified zinc finger binding proteins
Patent details — US 10344271
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 9, 2019
- Expiration
- Jul 4, 2039
- Applicant
- Sangamo Therapeutics, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K48/00
Quick answer
US 10344271 (Modified zinc finger binding proteins) is held by Sangamo Therapeutics, Inc.. Status: granted. Granted Jul 9, 2019. Expires Jul 4, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K48/00
More from Sangamo Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12318427
Methods and compositions for modulation of tau proteins
granted -
US 12139517
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
granted -
US 12043650
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
granted -
US 11981967
Engineering AAV
granted -
US 11981739
Chimeric antigen receptor specific for interleukin-23 receptor
granted -
US 11920169
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 11898158
Methods and compositions for the treatment of lysosomal storage diseases
granted -
US 11884930
Method of inactivating a glucocorticoid receptor gene in an isolated cell
granted
Frequently asked questions
What is US patent 10344271?
US 10344271 (Modified zinc finger binding proteins) is held by Sangamo Therapeutics, Inc.. Status: granted. Granted Jul 9, 2019. Expires Jul 4, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10344271?
Sangamo Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 192 pharmaceutical patents for this assignee.
When does US 10344271 expire?
Our index shows an expiration date of Jul 4, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.